Hypermethylation of Suppressor of Cytokine Signaling 1 in Hepatocellular Carcinoma Patients |
Saelee, Pensri
(Research Division, National Cancer Institute)
Chuensumran, Ubol (Department of Food Science and Technology, School of Culinary Arts, Suan Dusit Rajabhat University) Wongkham, Sopit (Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University) Chariyalertsak, Sunanta (Research Division, National Cancer Institute) Tiwawech, Danai (Research Division, National Cancer Institute) Petmitr, Songsak (Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University) |
1 | Arii S, Sata M, Sakamoto M, et al (2010). Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the japan society of hepatology (2009). Hepatol Res, 40, 667-85. DOI |
2 | Brakensiek K, Langer F, Schlegelberger B, et al (2005). Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol, 130, 209-17. DOI |
3 | Brysha M, Zhang JG, Bertolino P, et al (2001). Suppressor of cytokine signaling-1 attenuates the duration of interferon gamma signal transduction in vitro and in vivo. J Biol Chem, 276, 22086-9. DOI |
4 | Edmonson HA, Steiner PE (1954). Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer, 7, 462-503. DOI ScienceOn |
5 | Endo TA, Masuhara M, Yokouchi M, et al (1997). A new protein containing an SH2 domain that inhibits JAK kinases. Nature, 387, 921-4. DOI |
6 | Fischer JR, Ohnmacht U, Rieger N, et al (2007). Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer, 56, 115-23. DOI |
7 | Herman JG, Graff JR, Myohanen S, et al (1996). Methylation-specific PCRa novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 93, 9821-6. DOI ScienceOn |
8 | Herman JG, Latif F, Weng Y, et al (1994). Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A, 91, 9700-4. DOI ScienceOn |
9 | Kim DS, Kim MJ, Lee JY, et al (2007). Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer, 110, 2785-92. DOI ScienceOn |
10 | Kim YT, Park JY, Jeon YK, et al (2009). Aberrant promoter CpG island hypermethylation of the adenomatosis polyposis coli gene can serve as a good prognostic factor by affecting lymph node metastasis in squamous cell carcinoma of the esophagus. Dis Esophagus, 22, 143-50. DOI |
11 | Ko E, Kim SJ, Joh JW, et al (2008). CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma. Cancer Lett, 271, 240-50. DOI |
12 | Koelsche C, Strebovsky J, Baetz A, et al (2009). Structural and functional analysis of a nuclear localization signal in SOCS1. Mol Immunol, 46, 2474-80. DOI |
13 | Komazaki T, Nagai H, Emi M, et al (2004). Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol, 34, 191-4. DOI |
14 | Krtolica K, Krajnovic M, Usaj-Knezevic S, et al (2007). Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol, 13, 1187-94. DOI |
15 | Kuroki T, Trapasso F, Yendamuri S, et al (2003). Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res, 9, 1441-5. |
16 | Lee S, Cho NY, Yoo EJ, et al (2008). CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med, 132, 1657-65. |
17 | Miller SA, Dykes DD, Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16, 1215. DOI ScienceOn |
18 | Lehmann U, Wingen LU, Brakensiek K, et al (2007). Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum Mol Genet, 16, 1335-42. DOI |
19 | Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real- time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8. DOI ScienceOn |
20 | McClune AC, Tong MJ (2010). Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis, 14, 461-76. DOI |
21 | Naka T, Narazaki M, Hirata M, et al (1997). Structure and function of a new STAT-induced STAT inhibitor. Nature, 387, 924-9. DOI ScienceOn |
22 | Okochi O, Hibi K, Sakai M, et al (2003). Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res, 9, 5295-8. |
23 | Starr R, Willson TA, Viney EM, et al (1997). A family of cytokine-inducible inhibitors of signalling. Nature, 387, 917-21. DOI ScienceOn |
24 | Oshimo Y, Kuraoka K, Nakayama H, et al (2004). Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer, 112, 1003-9. DOI |
25 | Ramirez JL, Rosell R, Taron M, et al (2005). 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival. The Spanish Lung Cancer Group. J Clin Oncol, 23, 9105-12. DOI |
26 | Sporri B, Kovanen PE, Sasaki A, et al (2001). JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood, 97, 221-6. DOI |
27 | Ward AC, Touw I, Yoshimura A (2000). The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood, 95, 19-29. |
28 | Yang B, Guo M, Herman JG, et al (2003). Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol, 163, 1101-7. DOI |
29 | Whittaker S, Marais R, Zhu AX (2010). The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 29, 4989-5005. DOI |
30 | Wong IH (2001). Methylation profiling of human cancers in blood: molecular monitoring and prognostication (review). Int J Oncol, 19, 1319-24. |
31 | Yoshida T, Ogata H, Kamio M, et al (2004). SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med, 199, 1701-7. DOI |